Page 87 - 《中国药房》2024年5期

Kidney Int，2021，100（4S）：S1-S276. BMC Pharmacol Toxicol，2018，19（1）：14.
[ 2 ] 李馥伶，林美钦，宋洪涛，等. 影响他克莫司体内药动学 [11] LIAO M H，WANG M L，ZHU X，et al. Tacrolimus popu‐
参数、临床疗效的因素[J]. 中国药房，2016，27（2）： lation pharmacokinetic model in adult Chinese patients
279-282. with nephrotic syndrome and dosing regimen identifica‐
LI F L，LIN M Q，SONG H T，et al. Factors affecting tion using Monte Carlo simulations[J]. Ther Drug Monit，
pharmacokinetic parameters and clinical efficacy of tacro‐ 2022，44（5）：615-624.
limus in vivo[J]. China Pharm，2016，27（2）：279-282. [12] THÖLKING G，SCHÜTTE-NÜTGEN K，SCHMITZ J，
[ 3 ] ZHENG P，YU Z，LI L R，et al. Predicting blood concen‐ et al. A low tacrolimus concentration/dose ratio increases
tration of tacrolimus in patients with autoimmune diseases the risk for the development of acute calcineurin inhibitor-
using machine learning techniques based on real-world induced nephrotoxicity[J]. J Clin Med，2019，8（10）：1586.
evidence[J]. Front Pharmacol，2021，12：727245. [13] SONG J L，LI M，YAN L N，et al. Higher tacrolimus
[ 4 ] CHEN H X，CHENG Q，LI F，et al. Efficacy and safety of blood concentration is related to increased risk of post-
tacrolimus and low-dose prednisone in Chinese children transplantation diabetes mellitus after living donor liver
with steroid-resistant nephrotic syndrome[J]. World J Pediatr， transplantation[J]. Int J Surg，2018，51：17-23.
2020，16（2）：159-167. [14] 凌静，蒋艳，邹素兰，等. 肾病综合征患者他克莫司的群
[ 5 ] POPESCU M C，BALAS V E，PERESCU-POPESCU L， 体药动学研究[J]. 中国现代应用药学，2020，37（24）：
et al. Multilayer perceptron and neural networks[J]. 3019-3024.
WSEAS Trans Circuits Syst，2009，8（7）：579-588. LING J，JIANG Y，ZOU S L，et al. Population pharmaco‐
[ 6 ] LIANG T，SHEN J H，ZHANG S M，et al. Using kinetics of tacrolimus in patients with nephrotic syndrome
ultrasound-based multilayer perceptron to differentiate [J]. China Ind Econ，2020，37（24）：3019-3024.
early breast mucinous cancer and its subtypes from fibro‐ [15] HUANG Q B，LIN X B，WANG Y，et al. Tacrolimus phar‐
adenoma[J]. Front Oncol，2021，11：724656. macokinetics in pediatric nephrotic syndrome：a combina‐
[ 7 ] AKTER S，DAS D，HAQUE R U，et al. AD-CovNet：an tion of population pharmacokinetic modelling and ma‐
exploratory analysis using a hybrid deep learning model to chine learning approaches to improve individual prediction
handle data imbalance，predict fatality，and risk factors in [J]. Front Pharmacol，2022，13：942129.
Alzheimer’s patients with COVID-19[J]. Comput Biol [16] MO X L，CHEN X J，ZENG H S，et al. Tacrolimus in the
Med，2022，146：105657. treatment of childhood nephrotic syndrome：machine
[ 8 ] WADA T，ISHIMOTO T，NAKAYA I，et al. A digest of learning detects novel biomarkers and predicts efficacy[J].
the evidence-based clinical practice guideline for ne‐ Pharmacotherapy，2023，43（1）：43-52.
phrotic syndrome 2020[J]. Clin Exp Nephrol，2021，25 [17] YUAN W J，SUI L，XIN H L，et al. Discussion on ma‐
（12）：1277-1285. chine learning technology to predict tacrolimus blood con‐
[ 9 ] 中国成人肾病综合征免疫抑制治疗专家组. 中国成人肾 centration in patients with nephrotic syndrome and mem‐
病综合征免疫抑制治疗专家共识[J]. 中华肾脏病杂志， branous nephropathy in real-world settings[J]. BMC Med
2014，30（6）：467-474. Inform Decis Mak，2022，22（1）：336.
Expert Group on Immunosuppressive Therapy for Adult [18] BRUNET M，VAN GELDER T，ÅSBERG A，et al. Thera‐
Nephrotic Syndrome in China. Expert consensus on immu‐ peutic drug monitoring of tacrolimus-personalized
nosuppressive therapy for adult nephrotic syndrome in therapy：second consensus report[J]. Ther Drug Monit，
China[J]. Chin J Nephrol，2014，30（6）：467-474. 2019，41（3）：261-307.
[10] LI M，XU M，LIU W，et al. Effect of CYP3A4，CYP3A5 （收稿日期：2023-08-03 修回日期：2024-02-17）
and ABCB1 gene polymorphisms on the clinical efficacy （编辑：胡晓霖）
of tacrolimus in the treatment of nephrotic syndrome[J].

中国药房 2024年第35卷第5期 China Pharmacy 2024 Vol. 35 No. 5 · 589 ·